Skip to main content
Top
Published in: Diabetologia 2/2007

01-02-2007 | Short Communication

Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects

Authors: J. Tong, K. M. Utzschneider, D. B. Carr, S. Zraika, J. Udayasankar, F. Gerchman, R. H. Knopp, S. E. Kahn

Published in: Diabetologia | Issue 2/2007

Login to get access

Abstract

Aims/hypothesis

Pancreatic polypeptide (PP) is produced by the F-cells of the pancreas, and its plasma concentration has been used as a marker of parasympathetic activity. Recent work in rodents suggests that there is both sympathetic and parasympathetic innervation of white adipose tissue and that parasympathetic activity is anabolic resulting in lipid accumulation. We have examined whether in humans increased PP levels are associated with increased intra-abdominal fat (IAF), and thereby insulin resistance.

Materials and methods

We measured PP levels in 177 non-diabetic subjects (75 male/102 female; age 32–75 years) 3 min after an i.v. glucose bolus during a frequently sampled intravenous glucose tolerance test. IAF and s.c. fat (SCF) areas were measured by CT scan. The insulin sensitivity index (S I) was quantified using Bergman’s minimal model.

Results

PP levels were higher in men than in women (96.2 ± 72.2 vs 76.1 ± 55.0 pg/ml, mean ± SD, p = 0.037), as was IAF area (124.7 ± 67.4 vs 83.0 ± 57.7 cm2, p < 0.001). While PP levels were significantly associated with IAF (r = 0.16, p = 0.031), WHR (r = 0.30, p < 0.001) and age (r = 0.37, p < 0.01), they were not associated with SCF (r = 0.02, p = 0.829). The association between PP and IAF was not independent of age and/or sex. S I was negatively associated with PP levels (r = −0.17, p = 0.026) and IAF area (r = −0.65, p < 0.001). The association between S I and PP disappeared after adjusting for IAF area, indicating that S I was not a major determinant of PP levels.

Conclusions/interpretation

In humans, age and sex may modulate the association between plasma PP level and IAF area, suggesting that they may be determinants of parasympathetic activity and thus IAF accumulation.
Literature
1.
2.
go back to reference Kreier F, Fliers E, Voshol PJ et al (2002) Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications. J Clin Invest 110:1243–1250PubMedCrossRef Kreier F, Fliers E, Voshol PJ et al (2002) Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications. J Clin Invest 110:1243–1250PubMedCrossRef
3.
go back to reference Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M (1999) Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 20:1445–1448PubMedCrossRef Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M (1999) Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 20:1445–1448PubMedCrossRef
4.
go back to reference Batterham RL, Le Roux CW, Cohen MA et al (2003) Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88:3989–3992PubMedCrossRef Batterham RL, Le Roux CW, Cohen MA et al (2003) Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88:3989–3992PubMedCrossRef
5.
go back to reference Schwartz TW (1983) Pancreatic polypeptide: a unique model for vagal control of endocrine systems. J Auton Nerv Syst 9:99–111PubMedCrossRef Schwartz TW (1983) Pancreatic polypeptide: a unique model for vagal control of endocrine systems. J Auton Nerv Syst 9:99–111PubMedCrossRef
6.
go back to reference Cnop M, Landchild MJ, Vidal J et al (2002) The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005–1015PubMedCrossRef Cnop M, Landchild MJ, Vidal J et al (2002) The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005–1015PubMedCrossRef
7.
go back to reference Esler MD, Turner AG, Kaye DM et al (1995) Aging effects on human sympathetic neuronal function. Am J Physiol 268:R278–R285PubMed Esler MD, Turner AG, Kaye DM et al (1995) Aging effects on human sympathetic neuronal function. Am J Physiol 268:R278–R285PubMed
8.
go back to reference Brimnes Damholt M, Rasmussen BK, Hilsted L, Jensen R, Hilsted J (1997) Basal serum pancreatic polypeptide is dependent on age and gender in an adult population. Scand J Clin Lab Invest 57:695–702PubMedCrossRef Brimnes Damholt M, Rasmussen BK, Hilsted L, Jensen R, Hilsted J (1997) Basal serum pancreatic polypeptide is dependent on age and gender in an adult population. Scand J Clin Lab Invest 57:695–702PubMedCrossRef
9.
go back to reference Weyer C, Salbe AD, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA (2001) Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans? Metabolism 50:223–230PubMedCrossRef Weyer C, Salbe AD, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA (2001) Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans? Metabolism 50:223–230PubMedCrossRef
10.
go back to reference Vozarova de Courten B, Weyer C, Stefan N et al (2004) Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians. Diabetes 53:663–671PubMedCrossRef Vozarova de Courten B, Weyer C, Stefan N et al (2004) Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians. Diabetes 53:663–671PubMedCrossRef
Metadata
Title
Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects
Authors
J. Tong
K. M. Utzschneider
D. B. Carr
S. Zraika
J. Udayasankar
F. Gerchman
R. H. Knopp
S. E. Kahn
Publication date
01-02-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0553-4

Other articles of this Issue 2/2007

Diabetologia 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine